Bnp Paribas Asset Management Holding S.A. Krystal Biotech, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 174 shares of KRYS stock, worth $24,126. This represents 0.0% of its overall portfolio holdings.
Number of Shares
174Holding current value
$24,126% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
332Shares Held
24.4MCall Options Held
299KPut Options Held
97.6K-
Black Rock Inc. New York, NY3.95MShares$547 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.83MShares$392 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.73MShares$379 Million7.97% of portfolio
-
State Street Corp Boston, MA1.23MShares$170 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA954KShares$132 Million0.03% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.56B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...